CD274 and non-small cell lung carcinoma: In contrast, atezolizumab, a PD-L1 inhibitor, does not act on PD-1/PD-L2, which may minimize its effect on immune homeostasis and has shown efficacy in NSCLC with or without PD-L1 expression [10].